3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Central Nervous System Neoplasms
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
thymoglobulin
2
Thiotepa
2
Stem Cell Transplantation
2
Melphalan
2
Ifosfamide
2
Etoposide
2
Bone Marrow Transplantation
2
Antilymphocyte Serum
2
sodium thiosulfate
1
ribociclib
1
omburtamab I-131
1
lexatumumab
1
ganitumab
1
fludarabine phosphate
1
copanlisib
1
bempegaldesleukin
1
X-Rays
1
Vincristine
1
Topotecan
1
Temozolomide
1
Tacrolimus
1
Specimen Handling
1
Rituximab
1
Receptor Protein-Tyrosine Kinases
1
Radiotherapy, Intensity-Modulated
1
Radiosurgery
1
Polymerase Chain Reaction
1
Platinum
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Rhabdomyosarcoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts